DOCSLIB.ORG

1 Supplementary Figures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Supplementary Figures 1 Supplementary Figures CRISPR A B 3 Target F T A Scramble Jun JunD FosL1 Veh FosB KLA 1h IB: ATF3 BATF3 Jdp2 IB: Actin ATF2 BATF FosL2 IB: Jun JunD Jun ATF3 IB: Actin Fos JunB IB: JunD 0 2 4 6 8 10 12 Gene Expression (Log2 RPKM) IB: Actin C ) ) ) M 14 Up 2-fold 191 14 Up 2-fold 11 M 14 Up 2-fold 72 M K K Up 4 fold 943 K Up 4 fold 67 Up 4 fold 354 P P 12 P 12 12 R R R 10 10 10 Log2 8 8 Log2 8 Log2 A A A N N 6 N 6 6 R R R ( ( ( O 4 4 O 4 O K Down 2-fold 621 Down 2-fold 58 K Down 2-fold 297 K 3 2 2 D 2 F Down 4 fold 153 Down 4 fold 10 Down 4 fold 102 T Jun Jun A 0 0 0 0 2 4 6 8 10 12 14 0 2 4 6 8 10 12 14 0 2 4 6 8 10 12 14 Scamble Control (RNA Log2 RPKM) Scamble Control (RNA Log2 RPKM) Scamble Control (RNA Log2 RPKM) Supplementary Figure 1. A genome-wide map of AP-1 activity in macrophages. A. mRNA expression of all AP-1 monomers in Vehicle and 1-hour KLA treated TGEMs by RNA-seq. B. Western blot analysis of ATF3, Jun and JunD expression in CRISPR mediated knockout of ATF3, Jun and JunD in iBMDM cells. C. Scatterplots showing RNA-seq expression between scramble control and CRISPR mediated knockout of ATF3, Jun and JunD. 1 A B C chr19 46,310,000 2.5 Veh 125 _ Veh 40 Shared Nfkb2 KLA 1h ATF3 Fos KLA 1h 35 Jun 2.0 0 _ 30 JunD -seq (x10E4) P I chr19 88,530,000 1.5 25 40 _ Ifnb1 1.0 FosL2 -seq Peaks (Percent) 20 P I 0 _ 15 0.5 chr17: 5,670,000 10 0.0 50 _ Rela JunB Unique Ch 5 Number of Peaks Ch 3 F 100 80 60 40 20 Jun Fos T 0 _ Percentile Threshold JunB JunD A FosL2 5 kb D E Jun 262-KRMRNRIAASKCRKRKL-276 92,350,000 24,890,000 JunB 272-KRLRNRLAATKCRKRKL-286 chr19: chr17: JunD 237-KRLRNRIAASKCRKRKL-251 27 _ Cxcl10 50 _ Spsb3 Fos 143-RRERNKMAAAKCRNRRR-159 FosL2 130-RRERNKLAAAKCRNRRR-146 ATF3 100-RRERNKIAAAKCRNKKK-107 0 _ 0 _ DNA Contact * *** ** *** ** 27 _ 50 _ ag Count ag Count 0 _ 0 _ 27 _ 50 _ NormT NormT 0 _ 0 _ 5 kb 5 kb ATF3-ATF3 DBD ATF3-Jun DBD ATF3-Fosf DBD Supplementary Figure 2. Extended characterization of AP-1 binding cistrome. A. Quantification of the number of binding sites for each monomer that are present in vehicle, 1-hour KLA, or shared in both treatment conditions. B. Representative browser shots of ChIP-seq peaks for KLA specific monomers Fos (top), FosL2 (middle), and JunB (bottom). C. Percent of peaks that are unique to each monomer at different thresholds for the number of reads at each peak. 100 indicates 100% of the peaks and 10 indicates the top 10% of peaks when sorting by the number of reads. D. Protein alignment of AP-1 monomer DNA binding domains by Clustal Omega. Black background denotes identity while grey background denotes similar charge. Amino acids involved in DNA binding are indicated by stars. E. Representative browser shots of ChIP-seq peaks from ATF3 DNA binding domain chimeras at an ATF3 specific site (left) and Jun specific site (right). 2 Merge Cutoff Pearson Correlation >= 0.9 the left and right (withthat the are motif distinct logos from indicated). allsimilar other motifs motifs (Pearson (Pearson Correlation Correlation Hierarchical clustering of all motifsSupplementary in Figure the 3. JASPAR non-redundant library. Colored clades give highly 1 2 3 22 2 23 7 3 G G G .2 .2 .2 I I I L F F E E Curation of the JASPAR motif library to eliminate highly similar motifs. L Jun Fos L L wist2 S T T Atoh1 H H Nfe2 ::Jun Jdp2 T JunB JunD O A A O O L L O FosL1 Creb5 F Bhlha15 Neurog1 B Neurog2 Neurog2 F H H T Fos::Jun B A B Jun var Jdp2 var B JunD var ≥ 0.9, indicated by the dotted line) and blue leaf nodes give motifs Merged Motif Merged Motif < 0.9). Representative clades are indicated on 0.40 0.30 0.20 0.10 0.00 Correlation Difference 3 A C D 3.0 Six3 H1-hESC 2.5 ATF3 Hic Threshold Jun Lhx3 Rora-var JunD 4462 2.0 Nfil3 HepG2 Znf423 GM12878 1864 Zeb1 1.5 149 749 691 Dux4 77 532 Gfi1b 121 1482 1.0 Zfx 3630 4980 Absolute Likelihood Ratio 24174 of Motifs Passing Pax5 15 3202 1.0 1.5 2.0 2.5 3.0 3.5 3.9 Znf410 181 Threshold (-Log10 p-val) NfkB 701 Nkx2-5var2 365 3629 Znf263 29 163 Znf354c Myc 259 0.2 768 Mtf1 40 369 284 B Tead 650 3 rep1 0.0 Hnf1 5953298 F Fox 14226 28921 T A -0.2 PCC=0.98 Hnf4g Hnf4a SK-N-SH K562 Cebp 0.0 Nfi 0.25 ATF3 rep1 -0.25 Zic Rel TBA model Weight Zbtb33 Pou 0.2 Dbp-Hlf-Tef Nrf1 Elk-Etv eight 0.0 AP-1 CRE JunD rep2 PCC=0.97 AP-1 TRE -0.2 Ctcf Irf3/7/8/9 model W PU.1 0.0 A 0.25 -0.25 Pax2 B Jun rep1 T Duxa TBA model Weight Maf-Nrl eight >20 (positive) Runx MybL2 0.0 0.2 Gata MybL1 >20 (negative) model W 0.0 Egr A Sp4 B Jun rep2 -0.2 PCC=0.98 Tcfl5 T H C S S 0.0 0.25 E K562 -0.25 12878 JunD rep1 -N- HepG2 K M S H1-h TBA model Weight G Supplementary Figure 4. Characterization of TBA on individual replicate experiments and JunD ChIP- data from different cell lines. A. Distribution of the absolute ratio of the likelihood value for each motif that has mean likelihood below the threshold indicated on the horizontal axis, when comparing models trained on individual replicate experiments. Likelihood values for each individual replicate are calculated using the likelihood ratio test, and then averaged across 5 cross validation sets. Error bars indicate the standard deviation. B. Comparison of the weights of significant motifs (p<10e-2.5) from TBA models calculated from individual experiments. The similarity of each pair of models, measured by the Pearson correlation coefficient, is annotated in each panel. C. Significance values for the 20 most significant motifs for TBA models trained for JunD binding in a several of cell lines. Red hues indicate motifs positively correlated with binding and blue hues indicate motifs negatively correlated with binding. D. Overlap of JunD binding sites from various cell lines. Labels indicate the number of binding sites that overlap between a combination of the cell lines. 4 A C >4 1 Cebpα 16 MafB 3.0 ) 14 M 2 Cebpβ 17 MafY K 18 Myc P 3 Ctcf 12 R 4 E2f8 19 Nfe2L2 1.5 14 5 Egr1 20 NfκB2 Positivee 10 6 Egr2 21 Prdm1 5 11 0.0 12 6 2 7 Egr3 22 Rel 8 9 13 8 Etv3 23 Stat2 26 19 9 Fos 24 Tef 18 6 16 1 10 FosL2 25 Tfec 20 17 21 8 26 TgiF1 22 10 11 ID2 4 25 28 12 Irf1 27 Thap1 4 3 29 13 Jun 28 Usf1 Gene Expression (Log2 15 24 A 2 7 14 JunB 29 Zbtb7A L 23 K 27 15 Klf4 0.0 0 0 2 4 6 8 10 12 14 Motif Significance (-log10 pval) 1.5 Veh Gene Expression (Log2 RPKM) Negativee 3.0 >4 B Higher Positively Ranked Motifs Data in Table 1 ATF3 Jun Fos KLA FosL2 JunB JunD Data in Table 2 3 F Jun Fos Higher Negatively Ranked Motifs T JunB JunD A FosL2 KLA Supplementary Figure 5. TBA identifies motifs that coordinate the binding of each AP-1 monomer in KLA-1h treatment. A. mRNA expression of transcripts before and after KLA-1h treatment. Differentially expressed (FDR<0.05) factors with known DNA motifs are highlighted in red (up-regulated) and blue (down-regulated) , labeled and listed to the right. B. DNA motifs rank order based on the significance of the motif according to the likelihood ratio test. C. Heatmap representing the negative log10 p-value of each motif that shows a 100 fold likelihood ratio between two monomers when using the likelihood ratio test. 5 ) A M E K P Irf3/7/8/9 R PU.1 >5 Jun Fos Atf3 JunB JunD Gene Expression (Log2 FosL2 Balb/c Veh C57Bl6 Veh Balb/c KLA 1h B C57Bl6 KLA 1h reatment Train T Monomer Test 0.94 0.94 0.94 0.94 Positive Motifs (Log10 p-val) 0.95 0.94 0.95 0.94 Strain C57Bl/6 0.92 0.94 0.92 0.94 Balb/c 0.94 0.93 0.93 0.94 Treatment Veh 0.95 0.95 0.95 0.95 KLA-1h Monomer 0.94 0.94 0.94 0.94 ATF3 Jun 0.95 0.95 0.94 0.95 Fos JunB 0.93 0.93 0.92 0.94 JunD deltaSVM AP-1 TRE TBA-2Strain C AP-1 CRE TBA 0.6 Model Predictions 0.4 0.2 speciific binding A 0.0 L Correlation to Strain K -0.2 Individual Motifs 3 F Jun Fos T JunB JunD D A Positive Significant Motifs Negative Motifs (Log10 p-val) 0.14 ATF3 >5 Jun 0.12 Fos JunB 0.10 JunD 0.08 0.06 peaks with mutation in motif 0.04 AP-1 S Spi1-c S 0.02 Cebp 3 F Jun Fos 0.00 T JunB JunD 0.00 0.04 0.08 0.12 A Fraction SS peaks with mutation in motif 6 Fraction Non- Supplementary Figure 6.
Load more

Recommended publications
  • Multiple Facets of Jund Gene Expression Are Atypical Among AP-1 Family Members
    Oncogene (2008) 27, 4757–4767 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $30.00 www.nature.com/onc REVIEW Multiple facets of junD gene expression are atypical among AP-1 family members JM Hernandez1, DH Floyd2, KN Weilbaecher2, PL Green1,3 and K Boris-Lawrie1,3 1Department of Veterinary Biosciences and Center for Retrovirus Research, The Ohio State University, Columbus, OH, USA and 2Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St Louis, MO, USA and 3Department of Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA JunD is a versatile AP-1 transcription factor that can 2003; Milde-Langosch, 2005). The AP-1 component activate or repress a diverse collection of target genes. proteins are characterized structurally by their leucine- Precise control of junD expression and JunD protein– zipper dimerization motif and basic DNA-binding protein interactions modulate tumor angiogenesis, cellular domain. They can either activate or repress transcription differentiation, proliferation and apoptosis. Molecular and this versatile functional activity is dependent on the and clinical knowledge of two decades has revealed specific components of the dimeric complex and the that precise JunD activity is elaborated by interrelated cellular environment (Eferl and Wagner, 2003; Hess layers of constitutive transcriptional control, complex et al., 2004). AP-1 figures prominently in transcriptional post-transcriptional regulation and a collection of regulation of early response genes (reviewed by Jochum post-translational modifications and protein–protein et al., 2001; Mechta-Grigoriou et al., 2001; Eferl and interactions. The stakes are high, as inappropriate JunD Wagner, 2003).
    [Show full text]
  • The Activator Protein-1 Transcription Factor in Respiratory Epithelium Carcinogenesis
    Subject Review The Activator Protein-1 Transcription Factor in Respiratory Epithelium Carcinogenesis Michalis V. Karamouzis,1 Panagiotis A. Konstantinopoulos,1,2 and Athanasios G. Papavassiliou1 1Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece and 2Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts Abstract Much of the current anticancer research effort is focused on Respiratory epithelium cancers are the leading cause cell-surface receptors and their cognate upstream molecules of cancer-related death worldwide. The multistep natural because they provide the easiest route for drugs to affect history of carcinogenesis can be considered as a cellular behavior, whereas agents acting at the level of gradual accumulation of genetic and epigenetic transcription need to invade the nucleus. However, the aberrations, resulting in the deregulation of cellular therapeutic effect of surface receptor manipulation might be homeostasis. Growing evidence suggests that cross- considered less than specific because their actions are talk between membrane and nuclear receptor signaling modulated by complex interacting downstream signal trans- pathways along with the activator protein-1 (AP-1) duction pathways. A pivotal transcription factor during cascade and its cofactor network represent a pivotal respiratory epithelium carcinogenesis is activator protein-1 molecular circuitry participating directly or indirectly in (AP-1). AP-1–regulated genes include important modulators of respiratory epithelium carcinogenesis. The crucial role invasion and metastasis, proliferation, differentiation, and of AP-1 transcription factor renders it an appealing survival as well as genes associated with hypoxia and target of future nuclear-directed anticancer therapeutic angiogenesis (7). Nuclear-directed therapeutic strategies might and chemoprevention approaches.
    [Show full text]
  • Transcriptional Control of Tissue-Resident Memory T Cell Generation
    Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2019 © 2019 Filip Cvetkovski All rights reserved ABSTRACT Transcriptional control of tissue-resident memory T cell generation Filip Cvetkovski Tissue-resident memory T cells (TRM) are a non-circulating subset of memory that are maintained at sites of pathogen entry and mediate optimal protection against reinfection. Lung TRM can be generated in response to respiratory infection or vaccination, however, the molecular pathways involved in CD4+TRM establishment have not been defined. Here, we performed transcriptional profiling of influenza-specific lung CD4+TRM following influenza infection to identify pathways implicated in CD4+TRM generation and homeostasis. Lung CD4+TRM displayed a unique transcriptional profile distinct from spleen memory, including up-regulation of a gene network induced by the transcription factor IRF4, a known regulator of effector T cell differentiation. In addition, the gene expression profile of lung CD4+TRM was enriched in gene sets previously described in tissue-resident regulatory T cells. Up-regulation of immunomodulatory molecules such as CTLA-4, PD-1, and ICOS, suggested a potential regulatory role for CD4+TRM in tissues. Using loss-of-function genetic experiments in mice, we demonstrate that IRF4 is required for the generation of lung-localized pathogen-specific effector CD4+T cells during acute influenza infection. Influenza-specific IRF4−/− T cells failed to fully express CD44, and maintained high levels of CD62L compared to wild type, suggesting a defect in complete differentiation into lung-tropic effector T cells.
    [Show full text]
  • Accompanies CD8 T Cell Effector Function Global DNA Methylation
    Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer, Benjamin G. Barwick, Benjamin A. Youngblood, Rafi Ahmed and Jeremy M. Boss This information is current as of October 1, 2021. J Immunol 2013; 191:3419-3429; Prepublished online 16 August 2013; doi: 10.4049/jimmunol.1301395 http://www.jimmunol.org/content/191/6/3419 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130139 Material 5.DC1 References This article cites 81 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/191/6/3419.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer,* Benjamin G. Barwick,* Benjamin A. Youngblood,*,† Rafi Ahmed,*,† and Jeremy M.
    [Show full text]
  • Junb and GATA3 Transcription Factors Cytokine Expression Through Regulating CARMA1 Controls Th2 Cell-Specific
    CARMA1 Controls Th2 Cell-Specific Cytokine Expression through Regulating JunB and GATA3 Transcription Factors This information is current as Marzenna Blonska, Donghyun Joo, Patrick A. of September 27, 2021. Zweidler-McKay, Qingyu Zhao and Xin Lin J Immunol published online 27 February 2012 http://www.jimmunol.org/content/early/2012/02/26/jimmun ol.1102943 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/02/27/jimmunol.110294 Material 3.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 27, 2012, doi:10.4049/jimmunol.1102943 The Journal of Immunology CARMA1 Controls Th2 Cell-Specific Cytokine Expression through Regulating JunB and GATA3 Transcription Factors Marzenna Blonska,* Donghyun Joo,*,† Patrick A. Zweidler-McKay,‡ Qingyu Zhao,*,1 and Xin Lin*,† The scaffold protein CARMA1 is required for the TCR-induced lymphocyte activation.
    [Show full text]
  • Junb Differs from C-Jun in Its DNA- Binding and Dlmenzatlon Domains, and Represses C-Jun by Formation of Inactive Heterodimers
    Downloaded from genesdev.cshlp.org on October 3, 2021 - Published by Cold Spring Harbor Laboratory Press JunB differs from c-Jun in its DNA- binding and dlmenzatlon domains, and represses c-Jun by formation of inactive heterodimers Tiliang Deng and Michael Karin 1 Department of Pharmacology, Center for Molecular Genetics, University of California, San Diego, School of Medicine, La Jolla, California 92093-0636 USA JunB differs considerably from c-Jun in its ability to activate AP-l-responsive genes and induce oncogenic transformation. We demonstrate that the decreased ability of JunB to activate gene expression is the result of a small number of amino acid changes between its DNA-binding and dimerization motifs and the corresponding regions of c-Jun. These changes lead to a 10-fold decrease in the DNA-binding activity of Junk JunB can be converted into a c-Jun-like activator by substituting four amino acids in its DNA-binding and dimerization motifs with the corresponding c-Jun sequences. JunB can also attenuate trans-activation by c-Jun, an activity mediated by its leucine zipper. This ability depends on two glycine residues that decrease the stability of the JunB leucine zipper, resulting in decreased homodimerization and increased heterodimerization. These results illustrate how small changes in primary structure, including chemically conservative changes, can result in functional divergence of two highly related transcriptional regulators. [Key Words: JunB; c-Jun; DNA-binding/dimerization motifs; leucine zipper] Received October 16, 1992; revised version accepted December 29, 1992. Transcriptional control is commonly mediated by se- AP-1 was identified as a transcription factor required quence-specific DNA-binding proteins (Pabo and Saner for optimal activity of the human metallothionein IIA 1984; Johnson and McKnight 1989).
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • The Retinoblastoma Gene Family Members Prb and P107 Coactivate the AP-1-Dependent Mouse Tissue Factor Promoter in ®Broblasts
    Oncogene (2000) 19, 3352 ± 3362 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc The retinoblastoma gene family members pRB and p107 coactivate the AP-1-dependent mouse tissue factor promoter in ®broblasts Su-Ling Liu1, Arlymae Rand1, Robert J Kelm Jr,*,1 and Michael J Getz1,2 1Department of Biochemistry and Molecular Biology, Program in Tumor Biology, Mayo Clinic/Foundation, Rochester, Minnesota, MN 55905, USA Serum-stimulation of quiescent mouse ®broblasts results al., 1996), to maintenance of the placental labyrinth in transcriptional activation of tissue factor (TF), the during gestation (Erlich et al., 1999), and to tumor cellular initiator of blood coagulation. This requires the angiogenesis (Contrino et al., 1996). Tissue factor has rapid entry of c-Fos into speci®c AP-1 DNA-binding also been implicated as a determinant of metastatic complexes and can be strongly inhibited by the potential in melanoma cells (Mueller et al., 1992; adenovirus E1A 12S gene product. In this study, we Bromberg et al., 1995) and expression of TF in the utilized a panel of E1A mutants de®cient in cellular stromal compartment of breast carcinomas has been protein binding to analyse the molecular basis for E1A shown to correlate with progression to invasive inhibition of a minimal, c-Fos-dependent TF promoter/ cancer (Contrino et al., 1996; Vrana et al., 1996). reporter construct in mouse AKR-2B ®broblasts. Muta- Thus, it is important to understand how TF gene tions which impaired binding of the retinoblastoma tumor expression is regulated in both normal and neoplastic suppressor protein family members pRB, p107, and p130 cell types.
    [Show full text]
  • Jund Mutants with Spontaneously Acquired Transforming Potential
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 9369-9373, October 1993 Cell Biology JunD mutants with spontaneously acquired transforming potential have enhanced transactivating activity in combination with Fra-2 (AP-1/cellular transformation/spontaneous mutation/direct repeats/transactlvation) TAKASHI KAMEDA, ATSUKO AKAHORI, MARTHA H. SONOBE, TAKEHISA SUZUKI, ToSHINORI ENDO, AND HIDEO IBA* Department of Tumor Virus Research, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan Communicated by Hidesaburo Hanafusa, July 8, 1993 ABSTRACT Although a replication-competent retrovirus transforming activity at all (20, 21). When fos family genes that carries junD has no transforming activity in chicken such as c-fos (mouse) (22),fra-2 (chicken) (7),fra-1 (rat), and embryo fibroblasts, we have isolated mutant viruses that have fosB (mouse) (unpublished results) were introduced into spontaneously acquired transforming activity. The molecularly chicken embryo fibroblasts (CEFs) by replication-competent cloned junD genes of three such mutant viruses (Ti, T2, and retroviruses, all of them induced cellular transformation of T3) were shown to be responsible for the cellular transforma- CEFs. With regard to endogenous AP-1 components in tion. DNA sequence analysis indicated that a specific polynu- logarithmically growing CEFs and quiescent CEFs, the basal cleotide in the junD sequence was tandemly multiplied three level expression offra-2 (23, 24), c-jun (18, 20, 25), andjunD times or five times in Ti and T2, respectively. The repeated (21) has been reported, whereas c-fos expression is hardly polynucleotide encodes 16 amino acid residues that are located detectable in the absence of growth stimulation.
    [Show full text]
  • Jund (D17G2) Rabbit Mab A
    C 0 2 - t JunD (D17G2) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 0 0 Web: [email protected] 0 www.cellsignal.com 5 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP, IF-IC, F H Mk B Pg Endogenous 38, 42 Rabbit IgG P17535 3727 Product Usage Information organ defects during embryogenesis and die at E12.5 (7-10). JunD appears to specifically regulate genes involved in antioxidant response and hydrogen peroxide production and Application Dilution plays an important role in angiogenesis via its ability to exert transcriptional control over the VEGF gene (11). Furthermore, JunD appears to play an important roll in metabolism Western Blotting 1:1000 via modulation of IGF-I signaling pathways (12). Recent studies have shown that JunD Immunoprecipitation 1:200 regulates GADD45 α and γ expression in prostate cancer cells and that inhibition of JunD promotes apoptosis. Thus, JunD may be a viable therapeutic target for the treatment of Immunofluorescence (Immunocytochemistry) 1:400 prostate cancer (13). Flow Cytometry 1:200 1. Berger, I. and Shaul, Y. (1991) Oncogene 6, 561-6. 2. Hernandez, J.M. et al. (2008) Oncogene 27, 4757-67. Storage 3. Vinciguerra, M. et al. (2004) J Biol Chem 279, 9634-41. 4. Stocco, C.O. et al. (2002) J Biol Chem 277, 3293-302. Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% 5.
    [Show full text]
  • Virtual Chip-Seq: Predicting Transcription Factor Binding
    bioRxiv preprint doi: https://doi.org/10.1101/168419; this version posted March 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Virtual ChIP-seq: predicting transcription factor binding 2 by learning from the transcriptome 1,2,3 1,2,3,4,5 3 Mehran Karimzadeh and Michael M. Hoffman 1 4 Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada 2 5 Princess Margaret Cancer Centre, Toronto, ON, Canada 3 6 Vector Institute, Toronto, ON, Canada 4 7 Department of Computer Science, University of Toronto, Toronto, ON, Canada 5 8 Lead contact: michael.hoff[email protected] 9 March 8, 2019 10 Abstract 11 Motivation: 12 Identifying transcription factor binding sites is the first step in pinpointing non-coding mutations 13 that disrupt the regulatory function of transcription factors and promote disease. ChIP-seq is 14 the most common method for identifying binding sites, but performing it on patient samples is 15 hampered by the amount of available biological material and the cost of the experiment. Existing 16 methods for computational prediction of regulatory elements primarily predict binding in genomic 17 regions with sequence similarity to known transcription factor sequence preferences. This has limited 18 efficacy since most binding sites do not resemble known transcription factor sequence motifs, and 19 many transcription factors are not even sequence-specific. 20 Results: 21 We developed Virtual ChIP-seq, which predicts binding of individual transcription factors in new 22 cell types using an artificial neural network that integrates ChIP-seq results from other cell types 23 and chromatin accessibility data in the new cell type.
    [Show full text]
  • Alterations of NFIA in Chronic Malignant Myeloid Diseases
    Letters to the Editor 583 BACH2 is a B-cell specific transcription factor that induces 2Laboratoire d0He´matologie, CHU de Caen, Caen, France; 3 apoptosis in lymphoma cells and reduced expression has been De´parement de Genetique, Laboratoire Pasteur, Cerba, France and associated with poor prognostic outcome in diffuse large B-cell 4 lymphoma.7 Department of Haematology, John Radcliffe Hospital, Oxford, UK Our data also suggested that many components of the E-mail: [email protected] transforming growth factor-b (TGFb) signalling pathway are downregulated in PPBL (Supplementary Figure S3), including the tumour-suppressor molecule SMAD4 (Figure 1i; P ¼ 0.007). The TGFb pathway negatively regulates cell growth, and References inactivation of SMAD4 is present in over half of pancreatic 8 cancers and up to 35% of colorectal cancers. This is as far as 1 Mossafa H, Malaure H, Maynadie M, Valensi F, Schillinger F, we know the first description of the downregulation of SMAD4 Garand R et al. Persistent polyclonal B lymphocytosis with in a B-cell disorder. binucleated lymphocytes: a study of 25 cases. Groupe Francais PPBL represents a useful model for B-cell dysfunction as it d’Hematologie Cellulaire. Br J Haematol 1999; 104: 486–493. displays characteristics associated with benign (polyclonality, 2 Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene benign clinical course) and malignant disease (frequent chromo- 2007; 26: 1–10. somal abnormalities and aberrant B-cell morphology). Nearly all 3 Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin studies to date have sought to characterize the morphological or ME et al.
    [Show full text]